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AbstrACt
Objective Since most biomedical research focuses on a 
specific disease, evaluation of research output requires 
disease-specific bibliometric indicators. Currently used 
methods are insufficient. The aim of this study is to 
develop a method that enables detailed analysis of 
worldwide biomedical research output by disease.
Design We applied text mining techniques and analysis 
of author keywords to link publications to disease groups. 
Fractional counting was used to quantify disease-specific 
biomedical research output of an institution or country. 
We calculated global market shares of research output 
as a relative measure of publication volume. We defined 
‘top publications’ as the top 10% most cited publications 
per disease group worldwide. We used the percentage of 
publications from an institution or country that were top 
publications as an indicator of research quality.
results We were able to classify 54% of all 6.5 million 
biomedical publications in our database (based on Web 
of Science) to a disease group. We could classify 78% 
of these publications to a specific institution. We show 
that between 2000 and 2012,‘other infectious diseases’ 
were the largest disease group with 337 485 publications. 
Lifestyle diseases, cancers and mental disorders have 
grown most in research output. The USA was responsible 
for the largest number of top 10% most cited publications 
per disease group, with a global share of 45%. Iran 
(+3500%) and China (+700%) have grown most in 
research volume.
Conclusions The proposed method provides a tool to 
assess biomedical research output in new ways. It can be 
used for evaluation of historical research performance, 
to support decision-making in management of research 
portfolios, and to allocate research funding. Furthermore, 
using this method to link disease-specific research 
output to burden of disease can contribute to a better 
understanding of the societal impact of biomedical 
research.
IntrODuCtIOn 
One of the goals of biomedical research is 
to eradicate burden of disease. The grand 
societal challenges in European funding 
also build on the premise that (biomedical) 
research should contribute to prevention and 
treatment of diseases.1
Yet surprisingly, biomedical research output 
has not been systematically catalogued by 
diseases so far.2 Most publicly available metrics 
for analysing biomedical research by topic 
have severe limitations. Research fields in the 
Web of Science (WoS) database produced by 
Clarivate Analytics are defined at a too high 
level, since they cover a complete medical 
specialism.3 The Scopus database produced 
by Elsevier has the same problem. Medical 
Subject Headings (MeSH) terms4 are more 
specific, but are available only for a selection 
of journals.
Several authors have made efforts to analyse 
research output and funding at disease level, 
but only for a selection of diseases. Evans et 
al compared research output between coun-
tries for 19 disease groups, based on the 
International Classification of Disease, Ninth 
strengths and limitations of this study
 ► The proposed method offers quantitative insight 
in research quantity and quality for 269 disease 
groups. 
 ► The proposed method can be used for evaluation 
of historical research performance at disease level. 
It can support decision-making in management of 
research portfolios, showing relative strengths and 
weaknesses of institutions and countries, as well as 
identifying research gaps at national and global lev-
els. It can also be valuable in allocation of research 
funding.
 ► Author keywords were used instead of the stan-
dardised Medical Subject Headings descriptors, 
which are not available in the Web of Science 
database. 
 ► Research about, for instance, molecular mecha-
nisms, medical techniques and health sciences 
could often not be classified to a specific disease 
group and was thus not included in our results. 
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Revision (ICD-9) chapters.5 Gillum et al6 and Gross et 
al7 analysed burden of disease and research funding 
for a selection of 29 conditions, derived from the ICD. 
In various other studies funding, research output and 
burden of disease were described for specific diseases in 
a case by case approach. This was done, for example, for 
yellow fever8 and neglected tropical diseases.9 In other 
studies, total biomedical research output was analysed for 
specific countries10 11 or compared between countries.12 13
Text mining techniques are increasingly applied to 
biomedical text to uncover unseen relationships.14 In 
this study, we use these techniques to create a reference 
structure of disease groups and to catalogue publications 
accordingly. This opens a bridge between biomedical 
research output and other information available at disease 
level, which can contribute to a better understanding of 
the societal impact of biomedical science.
MethODs
selection of biomedical publications
The analysis was based on the Clarivate Analytics WoS 
database available at the Centre for Science and Tech-
nology Studies (CWTS) of Leiden University. Since the 
goal of this study is to quantify research output by disease, 
we included biomedical research fields only. Of the 250 
WoS research fields, we selected the 84 fields that are 
most medically oriented. We validated the selection by 
looking at the research output of the eight Dutch univer-
sity medical centres: over 98% of their publications were 
in one of these fields. Online supplementary appendix 1 
provides a full list of research fields included in this study. 
The dataset was compiled in June 2014. It includes all 
publications in the 84 selected research fields, published 
between 2000 and early 2014, with WoS document 
type ‘article’ or ‘review’. Not all publications from the 
first 6 months of 2014 were available, due to periodical 
updating of the CWTS in-house version of the WoS data-
base. The dataset contained 6.5 million publications in 
total.
Classification of publications by disease group
We defined 269 disease groups, based on the ICD-10 
classification and covering the full spectrum of this classi-
fication. We used a two-step approach to categorise publi-
cations to disease groups.
First, we categorised the author keywords listed by 
authors in their publications. In total, 158 700 unique 
author keywords were used in at least 10 publications in 
our dataset. Of these keywords, the 32 400 most frequently 
used keywords (used in more than 70 publications each) 
were short listed and further evaluated. Twenty-one per 
cent of these keywords were specific for a single-disease 
group. For example, the keyword ‘Alzheimer’s disease’ 
was linked to ‘dementia’. Many keywords were not suit-
able to use for categorisation to disease groups because 
they were either too general or not disease-specific. 
Examples of keywords not linked to a disease group are 
‘inflammation’ and ‘keyhole surgery’. We note that not 
all publications include author keywords.
In the second step, a text mining algorithm was used 
to search for disease-specific terms in titles and abstracts 
of publications. In this step, first a list of 10 983 unam-
biguous, disease-specific terms was generated by hand 
by medical professionals to characterise specific disease 
groups. Examples of terms for the disease group ‘malig-
nant neoplasm prostate’ include ‘prostate cancer’, 
‘prostate carcinoma’, ‘malignant tumour prostate’ and 
‘sarcoma prostate’. The generated disease-specific terms 
were then reviewed by another medical professional for 
ambiguity. Subsequently, publications with 1 of these 
10 983 terms in either title or abstract were assigned to the 
corresponding disease group. If the same publication was 
assigned to multiple disease groups, it was fully counted 
for all of them.
The method was validated in several ways. The first step 
was a manual examination of a random sample of 680 
publications assigned to a disease group. Subsequently, 
a random sample of 315 publications not assigned to a 
disease group was manually examined. The examina-
tion was executed by research professionals among 
whom research coordinators and a clinical librarian of 
the Dutch university medical centres. The percentage of 
publications that could be assigned to a disease group 
was compared between WoS research fields. In addition, 
several institutional profiles resulting from the classifica-
tion of research output to disease groups were discussed 
with researchers and deans from those institutions.
Classification of publications by institution and country
The name of an institution is often reported in many 
different ways in publications. Some authors, for example, 
report an abbreviated name while others report the full 
name, and some authors report the name of the univer-
sity with which a hospital is associated while other authors 
report only the name of the hospital itself. These incon-
sistencies are problematic when analysing the research 
output of institutions. We addressed this problem by 
relying on the categorisation of affiliations used in the 
CWTS Leiden Ranking 2014.15 In this way, we could 
compare the research output of the 750 largest univer-
sities worldwide (based on number of publications in 
WoS), of 1099 hospitals, and of 46 public research organ-
isations. Publications from all affiliations, also those not 
included in the selected institutions, were included when 
comparing research output between countries.
Publications were assigned fractionally to institutions 
and countries. This was done based on the number of 
addresses in the address list of a publication in which a 
certain institution or country is mentioned. For instance, 
if a publication includes five addresses and two of these 
addresses mention Leiden University (eg, two different 
departments within Leiden University), the publication 
is assigned to Leiden University with a weight of 2/5 = 
0.4. So the publication is not counted as a full publication 
for Leiden University but as 40% of a full publication. 
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This methodology is known as address-level fractional 
counting.16
Indicators of quantity and quality of research
We used several indicators of quantity and quality of 
biomedical research per disease group to provide quan-
titative insight in the research strengths of specific insti-
tutions and countries. Quantity was measured by the 
fractionally counted volume of publications of an institu-
tion or country. Citations are often seen as an indicator 
of scientific impact, or somewhat less precisely, as an 
indicator of quality. Since research fields differ in cita-
tion practices, comparison of citation counts between 
fields is difficult. Likewise, comparison of citation counts 
between older and more recent publications is problem-
atic, because older publications have had more time to 
accumulate citations. To overcome this, we identified for 
each combination of a disease group and a publication 
year the 10% most cited publications globally. We used 
the volume of these ‘top publications’ as an indicator of 
quality of output when comparing countries or institu-
tions. Only publications that appeared between 2000 and 
2012 were used to identify ‘top publications’, since publi-
cations after 2012 were too recent for the calculation of 
meaningful citation statistics in 2014. Self-citations, that 
is, citations given by an author to his or her own work, 
were excluded. For the comparison of research portfolios 
between countries, between institutions and over time, 
we used an institution’s (or country’s) share in the global 
publication volume per disease group as an indicator of 
the total volume (quantity). Additionally, we used the 
share of top publications in the total output of an insti-
tution (or country) as a size-independent indicator for 
quality. This relative measure enables a comparison of 
research output for different disease groups within the 
research portfolio of an institution (or country).
Patient and public involvement
No patients or public were involved in our study.
Results
This section first describes the results of the validation of 
our method. Second, results for several applications of 
the method are described.
Validation of the proposed method
We were able to relate 54% of all publications in the 
selected 84 research fields to a disease group, 3.2 million 
publications in total. Of all publications, 29% were 
assigned to a single-disease group, 14% to two disease 
groups and 11% to three or more disease groups. Fields 
of research with a large share of disease-specific publica-
tions were mainly clinical research fields. Over 80% of 
all publications in research fields, such as allergology, 
rheumatology and clinical neurology, were linked to a 
disease group. Research fields like ethics, microscopy and 
biophysics had a much lower percentage of disease-spe-
cific publications (10%, 17% and 27%, respectively). In 
these fields, we indeed would not expect a large share of 
the publications to be linked to a disease group, so the 
low percentages confirm that our method behaves as 
expected. We refer to online supplementary appendix 1 
for an overview of the share of disease-specific publica-
tions per research field.
Between 2000 and 2012, the annual volume of publi-
cations within the included research fields increased 
by 64%. In the same period, the volume of disease-spe-
cific publications increased by 92%. This means that 
disease-specific publications grew in share: from 48% in 
2000 to 57% of total volume in 2012. After manual veri-
fication, we found that 2% of the sample of disease-spe-
cific publications (n=680) were incorrectly assigned to a 
disease group, and 1% of the sample of uncategorised 
publications (n=315) were incorrectly not assigned to a 
disease group, both indicating the method to be accu-
rate. Incorrect links were mainly due to sentences such 
as ‘patients with diabetes were excluded’ in the abstracts 
of publications.
About 1900 institutions were analysed in this study. 
Together these institutions accounted for 69% of the 
address lines in disease-specific publications worldwide. 
Seventy-eight per cent of the disease-specific publications 
had at least one author from one of these institutions.
As expected, we found strong differences in the share 
of disease-specific publications between different types of 
research institutions in the Netherlands. We verified insti-
tution-specific results with researchers and deans of five 
top ranking institutions in the Netherlands and abroad. 
In all cases, the disease-specific research output was in 
line with their expectations about their own institution’s 
position in relation to other institutions worldwide.
Application 1: biomedical research output by disease group
Using our method, we can compare the research output 
between disease groups. The number of publications 
in the period 2000–2012 varies widely between disease 
groups, as shown in figure 1. ‘Other infectious diseases 
(not including HIV and tuberculosis)’ were the disease 
group with most publications. ‘Diabetes mellitus’, ‘meta-
bolic diseases’ and ‘mood disorders’ were also large. The 
number of publications on malignant neoplasms was just 
a little bigger than the total publication volume on heart 
diseases.
Interestingly, the worldwide research profile by 
disease is not constant over time. Some disease groups 
have seen a rapid growth in research output, while 
other disease groups have grown only mildly in research 
output, as shown in figure 2. Lifestyle diseases (obesity 
and diabetes), cancers (lung, prostate, colon and 
breast) and mental disorders (depression and other 
mental disorders) gained in share in the worldwide 
research portfolio. On the other hand, diseases such as 
anaemia, pain in chest and throat, leukaemia, and HIV 
show a decreasing share in the total research portfolio, 
although the research output has still grown in absolute 
volume.
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Application 2: biomedical research output by disease by 
country
The most cited disease-specific research publications origi-
nate from a small set of countries. Figure 3 shows the rela-
tive share of countries in the 10% most cited publications 
per disease group. The top 10 countries with the largest 
share in top 10% most cited research output account for 
83% of the total body of disease-specific publications world-
wide. Notably, the USA accounts for 45% of the top 10% 
most cited publications. There are however differences in 
research profiles between countries. For instance, Canada 
has equal shares in top publications on ‘depression’ and 
‘stroke’, while China has two times as many top publications 
on ‘stroke’ compared with ‘depression’.
It is possible to evaluate the development over time 
of each country’s share in publication volume for a 
specific disease. Figure 4 shows the growth in number 
of breast cancer publications by country between 
2000 and 2012. Although the number of publications 
of every country has grown during this period, some 
countries have grown faster than others. Most Western 
countries have grown slower than the world average. 
Countries that have grown faster than average are 
mainly developing economies, with China showing 
Figure 1 Research output per disease group. (Total volume of publications per disease group between 2000 and 
2012). Source: Gupta Strategists, CWTS, analysis based on Web of Science. CWTS, Centre for Science and Technology 
Studies. 
Figure 2 Growth in disease-specific research output by disease group. (Growth in number of publications between 2000 
and 2012, width represents total number of publications. Only the 40 disease groups with the most publications in 2012 are 
shown). The 40 disease groups with most publications in 2012 are shown here. Source: Gupta Strategists, CWTS, analysis 
based on Web of Science. CWTS, Centre for Science and Technology Studies; TB, tuberculosis. 
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700% growth. Notably, Iran experienced a remarkable 
3500% growth in research output, but its total volume 
of disease-specific publications remains small.
Application 3: research output by disease on an institution 
level
Our method allows for identification of institutions with 
a remarkable position in research on a specific disease 
group. We use multiple sclerosis (MS) as an example, 
but figure 5 can easily be constructed for all 269 disease 
groups used in this study. The figure shows for all institu-
tions their volume of MS publications and their respective 
share in the top 10% most cited publications about MS 
worldwide. Harvard’s unique position in MS research is 
illustrated by the facts that Harvard had the largest share 
in the total MS publication volume and that one in four of 
its publications was in the top 10% most cited publications 
about MS. Other centres with remarkable quantity and 
quality of MS research were University College London 
and VU University Amsterdam. A display like figure 5 
recognises institutions that have a high quality without a 
high production.
Using our method, it is possible to follow the research 
output of individual institutions for specific disease 
groups over time. As an example, figure 6 shows the rise 
of South African research output on HIV. Between 2000 
and 2004, the annual South African research output on 
HIV is relatively constant, but from 2005 onwards, several 
South African universities have grown rapidly, passing 
several famous HIV research institutions in volume. This 
growth seems partly due to growth of international collab-
oration. For instance, 10% of all South African publica-
tions on HIV were coauthored with Harvard University 
Figure 3 Distribution of top publications by country. (Share in 10% most cited publications within each disease 
category, 2000–2012). Source:  Gupta Strategists, CWTS, analysis based on Web of Science. AU, Australia; CA, Canada; CH, 
China; FR, France; GE, Germany; IT, Italy; JP, Japan; NL, Netherlands; CTWS, Centre for Science and Technology Studies.  
Figure 4 Growth in research output of breast cancer for the 30 largest countries. (Growth in number of publications between 
2000 and 2012, width represents total number of publications). Several of those countries were too small to get a text label in 
the graphic. Source: Gupta Strategists, CWTS, analysis based on Web of Science. CTWS, Centre for Science and Technology 
Studies; BRIC, Brazil, Russia, India and China. 
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in 2012, while this was only 2% in 2005. During this time, 
internationally renowned Harvard scientists such as Bruce 
Walker and Till Bärnighausen have started working part 
time for the University of Kwazulu-Natal.
In addition to comparing institutions for a specific 
disease, our method also allows us to map research 
portfolios of countries or institutions by disease, based 
on volume and top 10% publications. Using these port-
folio maps, we can now compare complete disease-spe-
cific research portfolios between institutions. As an 
example, we plotted portfolio maps of four universities 
in figure 7. Substantial differences in their profiles can 
easily be seen. Harvard University has much larger publi-
cation volumes than the three others. Imperial College 
has a large number of disease groups with at least 30% 
of their publications counting as top publications. Both 
University of Amsterdam and Karolinska Institute have a 
remarkable position in research on malignant oesopha-
geal neoplasms, whereas Imperial College does not.
DIsCussIOn
Our proposed method allows for systematic classification 
of publications in WoS to disease groups. We were able to 
classify 54% of all 6.5 million biomedical publications in 
the WoS database to a disease group. Between 2000 and 
2012, ‘other infectious diseases’ were the largest disease 
group with 337 485 publications. In this period, lifestyle 
Figure 5 Scientific output of MS by institution. (y-axis: share of institute’s output in total output, x-axis: % of publications 
in 10% most cited, 2000–2012. Only institutions with at least 20 publications about MS in study period were shown). Only 
instructions with at least 20 publications about MS between 2000 and 2012 are shown in figure. Source: Gupta Strategists, 
CWTS, analysis based on Web of Science. CTWS, Centre for Science and Technology Studies; MS, multiple sclerosis. 
Figure 6 HIV publication volume over time per university for selected universities. (y-axis: fractioned volume of peer-reviewed 
publications about HIV, x-axis: year). Source: Gupta Strategists, CWTS, analysis based on Web of Science. CTWS, Centre for 
Science and Technology Studies. 
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diseases, cancers and mental disorders have grown most 
in research output. On a country level, the USA was 
responsible for the largest number of top 10% most 
cited publications per disease group, with a global share 
of 45%. Iran (+3500%) and China (+700%) have grown 
most in research volume. On an institution level, we were 
able to relate 78% of biomedical publications to a specific 
institution. Below we describe some examples of potential 
use and then discuss possibilities for future research.
Potential value of the proposed method
The method can be used for evaluation of historical 
research performance at the level of specific diseases. It 
can support decision-making in management of research 
portfolios, showing relative strengths and weaknesses of 
institutions and countries. Combining these insights with 
indicators of innovation and research productivity17 can 
illustrate whether research performance is aligned with 
successful transfer of scientific knowledge to clinical 
practice.
Linking the disease-specific research output to burden 
of disease provides insights in ‘ white spots’ in global and 
regional research.18 These insights can support fact-based 
allocation of research funding, making it possible to better 
align research portfolios to local or global needs and to 
adjust portfolios to changes of those needs over time. 
This can be the starting point for further understanding 
of what drives research output other than burden of 
disease, for instance, economic strengths, political struc-
tures, research legacy, etc. Quantitatively unravelling the 
different drivers that determine disease-specific publica-
tion volume could provide insights in how we can realign 
research efforts across countries to have greater impact 
on reduction of disease burden.
Opportunities for additional research
Using disease groups based on the ICD-10 classification 
has the advantage of being exhaustive: all diseases can be 
included. When looking for research on a rare disease, 
the used classification system is not specific enough. 
However, our method can be adapted to answer such 
specific questions by using specific author keywords and 
tailor-made text phrases to look for in titles and abstracts. 
Addition of MeSH descriptors next to author keywords 
can further complete the method, although this requires 
the use of other bibliographic databases, since WoS does 
not include MeSH descriptors. Ultimately, the use of 
dynamic and customised research categories will make it 
easier to find the institutions with the strongest positions 
in research on specific diseases, thus answering portfolio 
questions in ways that are not possible yet.
Our method classifies each publication to disease 
nomenclature but does not categorise the nature of 
disease-specific research. For example, a publication 
classified to a disease group could describe a new gene 
involved in the pathogenesis, analyse the societal impact 
of the disease, or merely state the disease as a potential 
application for a new surgical technique. Ideally, the 
method should be supplemented with additional cate-
gories that, based on text mining, can identify the type 
of research and application. Also, clinical trial registers 
(eg, https://www. clin ical tria lsre gister. eu/ or https:// 
clinicaltrials. gov/) can be included. As an example, 
using a simple algorithm based on MeSH descriptors, it is 
Figure 7 Examples of institution research profiles. (y-axis: institutions share in global publication volume on disease group, 
x-axis: % of institutions publications that is in the global top 10% most cited, balls represent disease groups). HU, Harvard 
University; IC, Imperial College; KI, Karolinska Institute; UvA, University of Amsterdam.
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possible to identify cell-based, animal-based and patient-
based research.19
Now that publications are allocated to disease groups, 
bibliometric indicators of research quantity and quality 
can be combined with other information available on 
disease level. For instance, quality of care, patient-re-
ported health outcomes, cost of treatment and patents. 
This can be valuable in aligning research and healthcare 
portfolios of university medical centres.
COnClusIOn
We have shown that it is possible to systematically link 
research output to disease groups. Our method makes it 
possible to compare research output by countries or insti-
tutions and to monitor changes in biomedical research 
output over time or by disease. The novelty and value of 
the method is that it allows a disease-specific analysis, for 
instance, making it possible to compare research output 
with burden of disease. Since the major goal of biomed-
ical research is alleviation of disease burden, our method 
allows for evaluating current strengths and shortcomings.
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